Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Open accessAbstract
Alterations in cancer genomes strongly influence clinical responses to treatment and in many instances are potent biomarkers for response to drugs. The Genomics of Drug Sensitivity in Cancer (GDSC) database (www.cancerRxgene.org) is the largest public resource for information on drug sensitivity in cancer cells and molecular markers of drug response. Data are freely available without restriction. GDSC currently contains drug sensitivity data for almost 75 000 experiments, describing response to 138 anticancer drugs across almost 700 cancer cell lines. To identify molecular markers of drug response, cell line drug sensitivity data are integrated with large genomic datasets obtained from the Catalogue of Somatic Mutations in Cancer database, including information on somatic mutations in cancer genes, gene amplification and deletion, tissue type and transcriptional data. Analysis of GDSC data is through a web portal focused on identifying molecular biomarkers of drug sensitivity based on queries of specific anticancer drugs or cancer genes. Graphical representations of the data are used throughout with links to related resources and all datasets are fully downloadable. GDSC provides a unique resource incorporating large drug sensitivity and genomic datasets to facilitate the discovery of new therapeutic biomarkers for cancer therapies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The sensitivity of MDM2 inhibitors against cancer cells is influenced by more criteria other than p53 mutation.
“Taking Nutlin-3a as an example, the sensitivity of MDM2 inhibitors against cancer cells was influenced by more criteria other than p53 mutation [92].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · see citing works
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,442 · see citing works
Self-citationFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O’Brien, S. G., Gathmann, I., Kantarjian, H. M., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,473 · see citing works
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · see citing works
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · see citing works
Self-citationPubChem: Integrated Platform of Small Molecules and Biological Activities
Bolton, E., Wang, Y., Thiessen, P. A., & Bryant, S. H. (2008) · Annual reports in computational chemistry · doi:10.1016/s1574-1400(08)00012-1 · Cited by 1,267 · see citing works
Reorganizing the protein space at the Universal Protein Resource (UniProt)
The UniProt Consortium (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr981 · Cited by 1,223 · see citing works
A transposase strategy for creating libraries of circularly permuted proteins
Mehta, M., Liu, S., & Silberg, J. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks060 · Cited by 1,042 · see citing works
Exploring the Genomes of Cancer Cells: Progress and Promise
Stratton, M. R. (2011) · Science · doi:10.1126/science.1204040 · Cited by 688 · see citing works
Self-citationAnnual Reports in Computational Chemistry
(2009) · Annual reports in computational chemistry · doi:10.1016/s1574-1400(09)00513-1 · Cited by 386 · see citing works
McDermott, U., Sharma, S. V., Dowell, L., Greninger, P., Montagut, C. O., Lamb, J. A., Archibald, H., Raudales, R., Tam, A., Lee, D. W., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707498104 · Cited by 356 · see citing works
Self-citationDo molecularly targeted agents in oncology have reduced attrition rates?
Walker, I. A. L., & Newell, H. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2758 · Cited by 128 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Genetic and transcriptional evolution alters cancer cell line drug response
Ben-David, U., Siranosian, B., Ha, G., Tang, H., Oren, Y., Hinohara, K., Strathdee, C. A., Dempster, J., Lyons, N. J., Burns, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0409-3 · Cited by 931 · see citing works
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893 · see citing works
The Cellosaurus, a Cell-Line Knowledge Resource
Bairoch, A. (2018) · Journal of Biomolecular Techniques JBT · doi:10.7171/jbt.18-2902-002 · Cited by 807 · see citing works
Artificial Intelligence in Cancer Research and Precision Medicine
Bhinder, B., Gilvary, C., Madhukar, N. S., & Elemento, O. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0090 · Cited by 781 · see citing works
Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730 · see citing works
Predicting drug response and synergy using a deep learning model of human cancer cells
Kuenzi, B. M., Park, J., Fong, S. H., Sanchez, K. S., Lee, J., Kreisberg, J. F., Ma, J., & Ideker, T. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.014 · Cited by 544 · see citing works
Effective drug combinations in breast, colon and pancreatic cancer cells
Jaaks, P., Coker, E. A., Vis, D. J., Edwards, O., Carpenter, E. F., Leto, S. M., Dwane, L., Sassi, F., Lightfoot, H., Barthorpe, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04437-2 · Cited by 469 · see citing works
Self-citationMOLI: multi-omics late integration with deep neural networks for drug response prediction
Sharifi-Noghabi, H., Zolotareva, O., Collins, C. C., & Ester, M. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz318 · Cited by 421 · see citing works
Lito, P., Saborowski, A., Yue, J., Solomon, M., Joseph, E., Gadal, S., Saborowski, M., Kastenhuber, E., Fellmann, C., Ohara, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.011 · Cited by 324 · see citing works
Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223 · see citing works
A genome-wide positioning systems network algorithm for in silico drug repurposing
Cheng, F., Lu, W., Liu, C., Fang, J., Hou, Y., Handy, D. E., Wang, R., Zhao, Y., Yang, Y., Huang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10744-6 · Cited by 215 · see citing works
Predicting responses to platin chemotherapy agents with biochemically-inspired machine learning
Mucaki, E. J., Zhao, J. Z. L., Lizotte, D. J., & Rogan, P. K. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0034-5 · Cited by 200 · see citing works
CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer
Lin, A., Qi, C., Wei, T., Li, M., Cheng, Q., Liu, Z., Luo, P., & Zhang, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac129 · Cited by 152 · see citing works
EWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma
Iniguez, A. B., Stolte, B., Wang, E. J., Conway, A. S., Alexe, G., Dharia, N. V., Kwiatkowski, N., Zhang, T., Abraham, B. J., Mora, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.009 · Cited by 173 · see citing works
Self-citationHarnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., & Chen, X. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0240-9 · Cited by 154 · see citing works
Fröhlich, F., Kessler, T., Weindl, D., Shadrin, A., Schmiester, L., Hache, H., Muradyan, A., Schütte, M., Lim, J.-H., Heinig, M., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.10.013 · Cited by 143 · see citing works
Machine learning for perturbational single-cell omics
Ji, Y., Lotfollahi, M., Wolf, F. A., & Theis, F. J. (2021) · Cell Systems · doi:10.1016/j.cels.2021.05.016 · Cited by 137 · see citing works
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121 · see citing works
Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome
Tsvetkov, P., Mendillo, M. L., Zhao, J., Carette, J. E., Merrill, P. H., Cikes, D., Varadarajan, M., van Diemen, F. R., Penninger, J. M., Goldberg, A. L., et al. (2015) · eLife · doi:10.7554/elife.08467 · Cited by 83 · see citing works
Knijnenburg, T. A., Klau, G. W., Iorio, F., Garnett, M. J., McDermott, U., Shmulevich, I., & Wessels, L. F. A. (2016) · Scientific Reports · doi:10.1038/srep36812 · Cited by 74 · see citing works
Self-citationPathway-Guided Deep Neural Network toward Interpretable and Predictive Modeling of Drug Sensitivity
Deng, L., Cai, Y., Zhang, W., Yang, W., Gao, B., & Liu, H. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00331 · Cited by 71 · see citing works
Self-citationMultilevel models Improve precision and Speed of IC <sub>50</sub> Estimates
Vis, D. J., Bombardelli, L., Lightfoot, H., Iorio, F., Garnett, M. J., & Wessels, L. F. (2016) · Pharmacogenomics · doi:10.2217/pgs.16.15 · Cited by 71 · see citing works
Self-citationPINA 3.0: mining cancer interactome
Du, Y., Cai, M., Xing, X., Ji, J., Yang, E., & Wu, J. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1075 · Cited by 60 · see citing works
Li, M., Lin, A., Luo, P., Shen, W., Xiao, D., Gou, L., Zhang, J., & Guo, L. (2020) · Aging · doi:10.18632/aging.102683 · Cited by 62 · see citing works
High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need
Hughes, R. E., Elliott, R. J. R., Dawson, J. C., & Carragher, N. O. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.02.015 · Cited by 62 · see citing works
Yi, R., Lin, A., Cao, M., Xu, A., Luo, P., & Zhang, J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00933 · Cited by 60 · see citing works
ASGARD is a single-cell guided pipeline to aid repurposing of drugs
He, B., Xiao, Y., Liang, H., Huang, Q., Du, Y., Li, Y., Garmire, D., Sun, D., & Garmire, L. X. (2023) · Nature Communications · doi:10.1038/s41467-023-36637-3 · Cited by 57 · see citing works
Yang, H., Liang, S.-Q., Xu, D., Yang, Z., Marti, T. M., Gao, Y., Kocher, G. J., Zhao, H., Schmid, R. A., & Peng, R.-W. (2019) · Oncogenesis · doi:10.1038/s41389-019-0158-7 · Cited by 58 · see citing works
Fowles, J. S., Dailey, D. D., Gustafson, D. L., Thamm, D. H., & Duval, D. L. (2017) · Veterinary and Comparative Oncology · doi:10.1111/vco.12192 · Cited by 49 · see citing works
Artificial intelligence in radiotherapy
Li, G., Wu, X., & Ma, X. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.005 · Cited by 46 · see citing works
Shee, K., Wells, J. D., Jiang, A., & Miller, T. W. (2019) · PLOS ONE · doi:10.1371/journal.pone.0224267 · Cited by 43 · see citing works
“Robust Multi-array Average (RMA)-normalized transcriptomic data and drug sensitivity data [area under the curve (AUC) and IC50] were downloaded for A) 860 cancer cell lines and 481 drugs from the Cancer Therapeutics Response Portal (CTRP) [4], B) 1,065 cancer cell lines and 266 drugs from the Genomics of Drug Sensitiv…”
MethodEfforts to Develop KRAS Inhibitors
Holderfield, M. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031864 · Cited by 43 · see citing works
Incorporating biological structure into machine learning models in biomedicine
Crawford, J., & Greene, C. S. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.12.021 · Cited by 41 · see citing works
Naulaerts, S., Dang, C. C., & Ballester, P. J. (2017) · Oncotarget · doi:10.18632/oncotarget.20923 · Cited by 41 · see citing works
Yi, R., Hong, S., Zhang, Y., Lin, A., Ying, H., Zou, W., Wang, Q., Wei, T., Cheng, Q., Zhu, W., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.757137 · Cited by 37 · see citing works
Wu, Y., Liu, Q., Qiu, Y., & Xie, L. (2022) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010367 · Cited by 34 · see citing works
Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas
Mudianto, T., Campbell, K. M., Webb, J., Zolkind, P., Skidmore, Z. L., Riley, R., Barnell, E. K., Ozgenc, I., Giri, T., Dunn, G. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4179 · Cited by 33 · see citing works
Computational estimation of quality and clinical relevance of cancer cell lines
Trastulla, L., Noorbakhsh, J., Vazquez, F., McFarland, J., & Iorio, F. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211017 · Cited by 31 · see citing works
The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215677 · Cited by 26 · see citing works
Liang, J., Li, Z.-W., Yue, C.-T., Hu, Z., Cheng, H., Liu, Z.-X., & Guo, W.-F. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac254 · Cited by 23 · see citing works
Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature
Scarborough, J. A., Eschrich, S. A., Torres-Roca, J., Dhawan, A., & Scott, J. G. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00375-y · Cited by 14 · see citing works
scDrugMap: benchmarking large foundation models for drug response prediction
Wang, Q., Pan, Y., Zhou, M., Tang, Z., Wang, Y., Wang, G., & Song, Q. (2025) · Nature Communications · doi:10.1038/s41467-025-67481-2 · Cited by 12 · see citing works
An, H., Fang, W., Chen, H., Huang, W., Liu, H., Zhang, Z., Zhao, H., Zhang, Y., Zhao, M., Qiu, J., et al. (2025) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2025.108929 · Cited by 6 · see citing works
Xie, Y., Peng, J., & Zhou, Y. (2019) · doi:10.21203/rs.2.18936/v1 · Cited by 5 · see citing works
Wei, R., Dai, H., Zhang, J., Shih, D. J. H., Liang, Y., Xiao, P., McGrail, D. J., & Lin, S.-Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095008 · Cited by 4 · see citing works
- Authors
- Yang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., Ramaswamy, S., Futreal, P. A., Haber, D. A., Stratton, M. R., Benes, C., McDermott, U., & Garnett, M. J.
- Affiliations
- Howard Hughes Medical Institute (US)
- Corresponding author
- McDermott, Ultan
- Garnett, Mathew J.
- ORCID
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11-22
- Volume
- 41
- Issue
- D1
- Pages
- D955-D961
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC3531057
- OpenAlex
- W2108068107
- Cited by
- 4,051
- References
- 13
- Citations by year
- 2026: 321 · 2025: 573 · 2024: 669 · 2023: 640 · 2022: 669 · 2021: 356 · 2020: 237 · 2019: 181 · 2018: 121 · 2017: 88 · 2016: 83 · 2015: 52 · 2014: 39 · 2013: 13 · 2012: 3
- FWCI
- 11.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- Wellcome Trust (086357)
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- drug sensitivity, cancer cell lines, therapeutic biomarkers, anticancer agents, somatic mutations, gene amplification, gene deletion, drug response, cancer genomics, drug repurposing
- MeSH terms
- Antineoplastic Agents, Computer Graphics, Genetic Markers, Humans, Mutation, Neoplasms, Internet, Genomics, Databases, Genetic, Cell Line, Tumor, Genes, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
